Tag Archives: animal research

End of Primate Research at the University of Toronto?

Intended or not, comments by a university administrator and veterinarian in some Canadian news articles last week likely gave some readers a distorted view not only of the status of research at the University of Toronto, but of animal research more broadly. A pair of articles reported that primate research at the U of T had ended.  In one titled “University of Toronto stops research on live monkeys” a university official explains:

“They were our very last ‘non-human’ primates and we have no intention of using any more. Technology now lets us get the same information from smaller animals,” said Peter Lewis, the U of T’s associate vice-president of research.”

Except that the press coverage also says that the U of T scientist Prof. Barry Sessle, whose highly regarded research orofacial pain and neuromuscular function and dysfunction straddles both laboratory animal research and clinical research involving human subjects, will “continue to do monkey studies in partnership with a lab in Chicago.”  We are also aware that University of Toronto researchers undertake primate research even closer to home at another research institute in Toronto. Does the U of T administration exclude their own faculty from the “we” in the “we have no intention of using any more [primates]” statement?
In an article headlined “With last monkeys dead, U of T sees a shift in animal research,” the university’s veterinarian adds his view of the need for primates in research.

“Across the country, Dr. Harapa has watched the appetite for research primates waning. Their cost and availability are factors, and universities do feel some ethical pressure, he said. “But the main reason is that people have just adopted other animals for their experimental needs – mostly rats and mice.

Comments by Lewis and Harapa raise a number of questions. Foremost, we wonder whether U of T might want to correct any possible misimpression that their comments apply only to their own research programs, which are apparently now suited by a restricted range of animal models?  For example, Lewis’ statement that: “Technology now lets us get the same information from smaller animals.” obviously applies to a subdomain of study, as do Harapa’s comments:

“We stopped using dogs and cats a few years ago too. We can do so much research now by genetically modifying a mouse,” said Harapa. “Under a sector microscope you would hardly know the difference between a human heart and that of a mouse.

While these thoughts may be relevant to specific work at U of T, they are obviously not meant to be applicable to the broad set of research questions under study elsewhere.  We are well aware that genetically modified mice and rats are an increasingly powerful tool for biomedical research, but they cannot yet replace species such as dogs, pigs and macaques in all necessary studies.


Some institutions may find it tempting to dodge public controversy by allowing a perception that the absence of on-site animal research reflects an institution’s commitment to not participate, support, or benefit from that work. Encouraging that public perception is an easy path to gain favor with animal activists and other opponents. But this is not a good path, if for no other reason than the fact that solving a research problem involves a range of animal models at various points in time. It is disingenuous to deny the value of research with a particular species because your institution has decided to discontinue working with that species. If nothing else, those inclined to dodge should consider that they are deriving benefit from the work of their colleagues at the institutions still willing to assume the risk and responsibility. That argues in favor of acknowledging the value of the work in your public statements.

It is unfortunate that these articles contain no comments by either Harapa or Lewis that might improve public appreciation of the value of a range of animal models, or any statement of support for the valuable research undertaken by Prof. Sessle, whose primate studies drew the attention of animal rights activists.

Allyson Bennett

A welcome end to random-source dog and cat dealers

The National Institutes of Health has announced that starting October 1, 2012, NIH funds may no longer be used to buy cats from Class B dealers. A similar prohibition in the purchase of dogs from Class B dealers takes effect in 2015.

Although dogs and cats constitute only small percentage of research animals, they have been used in American biomedical research for over a century for studies of cardiovascular and neurological diseases, and for other areas of research including recent studies that led to a gene therapy for the eye disease Leber’s congenital amaurosis, whose success was reported widely last week.  The use of these animals is tightly regulated by the Animal Welfare Act, and they are only employed for studies where lower species do not provide adequate models.

Class B dealers are individuals licensed by the USDA under the Animal Welfare Act to resell animals they did not breed themselves. Class A dealers are breeders who do raise the animals themselves. Class B dealers may purchase dogs and cats from sources such as municipal pounds, from individuals who bred and raised the animals, and from other licensed dealers. They are required to keep records on where they got each animal and to hold pound animals for a minimum period so that if an unwanted animal was actually a stray, the owner has time to reclaim it.

Animal statistics in 2010 (US data) - Dogs account of 0.25% and cats 0.08% of the total number of animals used.

Class B dealers used to provide a large number of cats and dogs for research because they were virtually the only source for older animals and for some breeds. Regrettably, some Class B dealers used practices that violated the Animal Welfare Act both in terms of how they acquired animals and how they treated them.  The National Academies of Science studied the specific areas of science where Class B dogs and cats were being used and concluded that NIH could develop alternate supply mechanisms to replace them. NIH decided the best way to facilitate the transition was to provide an initial outlay of funds so that Class A dealers could begin raising older dogs of the breeds required for scientific research. It is expected that these breeders will be able to produce the necessary animals by 2015.

After October 1, 2012, NIH-grant supported research can only use cats from the following sources: Class A dealers, privately owned research colonies, or client owned animals, such as animals that participate in veterinary clinical trials.  The same policy will apply to dogs in 2015 when the Class A breeding program is in full swing.

The transition of NIH-funded research away from the use of Class B dogs and cats is an example of how measures can be taken to correct ethical problems regarding the treatment of animals.  When ethical concerns exist, thoughtful and deliberate steps can address those concerns, while preserving important biomedical research projects.

Bill Yates and Alice Ra’anan.

Bill Yates is the Chair of American Physiological Society Animal Care and Experimentation Committee. Alice Ra’anan is Director of Science Policy for the American Physiological Society. The views expressed above are exclusively those of Bill Yates and Alice Ra’anan and do not necessarily represent those of their employers.

Pop Quiz!

Take out a piece of paper and a sharpened #2 pencil.

Please read carefully the following story and answer all the questions.

You have 15 min.

One Saturday morning Dr. X was walking her dog thinking about some recent results in her field when it dawned on her that she might actually have the key to explaining all those findings.  If she was correct, she could go on to develop a new therapy for a terrible disease.

Being a scientist, Dr. X rapidly turned that idea into a specific hypothesis with testable predictions.  She ran back to her laboratory, gathered her students, told them the idea, and got to work.  They were excited when their first test (T1) yielded a positive result.  This simply meant that the implications of her hypothesis were corroborated by the experiment.  Good job everyone!

The next day her students were up all night running the second test (T2).  Dr. X arrived at the laboratory after dropping her kids in school to find very tired students, but with big smiles on their faces.  The second test, she correctly guessed, gave them another positive result.  Hurrah!

That night, at the dinner table, she shared the excitement with her family. Even the dog appeared to notice something important was going on. Next morning, one of her postdoctoral students came up with, what appeared to be, a direct test of the central idea.  It was agreed at the Lab meeting that this would be the next experiment (T3).

It was a difficult experiment.  Dr. X’s husband agreed to pick up the kids instead and let her finish her work.  Close to midnight the results came in.  Everyone in the lab ran to see the results.   They stared at each other in disappointment.  The result was clearly negative — what this meant is that the outcome contradicted a key prediction of the hypothesis.

Dr. X’s Lab had a difficult month.  They went over the data over and over again — nothing was obviously wrong; but they decided not to give up.  Instead, they brainstormed about how they could come up with a new hypothesis that may explain the data they had collected so far.  And yes, Dr. X explained, this must include a reason for the outcome of the negative experiment as well.

One night, Dr. X was awoken by the sound of the phone. She was startled, it was unusual that anyone would call at 3 am to her home. Understandably, Dr. X answered the phone with some apprehension.  She was relieved to hear one of her students, which after calming himself down and apologizing for the time, described to her a new idea that, he said, came to him out of nowhere in the middle of his sleep.  She grumbles, but listened…  her sleepy eyes slowly widening as the student went on.  When he was done Dr. X immediately knew that there was no doubt her student could explain the diverse findings.

Everyone gathered in the laboratory next morning and started to test again based on the new concept over the week.  T4… positive!  T5….positive!  T6… negative…  Negative?!  Oh no…  Again?!

Yes, again.  But Dr. X gathered her students and explain to them that this is how science works.  New ideas emerge from old ones in an effort to account for all the data their community gathered so far.  And that negative findings were important for science too. They all felt a bit better as they went home… just a little bit.  But more than Dr. X’s words, it was a group feeling that they were getting closer to the truth.

It took her Lab a few more iterations of this difficult game called science, but one day they knew they had nailed it.  They had a new idea that not only explained all past results but stood many additional tests, including replications by her colleagues.  Their work delivered a medical breakthrough that allowed them to develop a new medical treatment that saved uncountable human lives.

Questions:

Assume that in this story, from beginning to end, including her experiments those of her colleagues, scientists performed 20 experimental tests that yielded positive results, 15 experimental tests that yielded negative results, and that each test required the use of exactly one mouse.

Q1. How many mice were scientifically necessary to develop this medical breakthrough?

Q2. Which experimental tests were more important in developing this breakthrough?  The tests yielding positive results or the ones yielding negative results?  Explain.

Q3. Given the end result was that uncountable human lives are being saved.  Which test was morally justifiable and which was not?  Were positive tests in any way more justifiable than negative ones?  Were experiments used in replicating Dr. X’s findings necessary and justified?  Or is it only the final experiment directly preceding the development of the new therapy that was justified?

Q4. Five years after her discovery, and with the new knowledge acquired, one of Dr. X’s colleagues comments that it was obvious some of the ideas she had tried could not have worked.  With 20/20 vision, Dr. X agrees.  Does her admission mean the experiments testing those ideas were scientifically unnecessary or ethically indefensible?

Submit your answers in the comments section below!

How nerve cells reach their niche.

Developmental biology, the study of the processes through which organisms grow and develop, is an area of biomedical research where modal organisms – ranging from the slime mold Dictyostelium  discoideum to the chicken – play a crucial role, and one that has been honoured with several  Nobel Prizes in recent years.  For example, the 1995 prize for “discoveries concerning the genetic control of early embryonic development” was awarded for studies of the fruit fly  Drosophila melanogaster , and the  2002 prize for “discoveries concerning ‘genetic regulation of organ development and programmed cell death”, was awarded for research undertaken with the nematode worm Caenorhabditis elegans, while the 2007 prize for  “discoveries of “principles for introducing specific gene modifications in mice by the use of embryonic stem cells”” depended on studies of stem cells in the developing mouse embryo undertaken by Martin Evans.

Today on the Neurophilosophy blog Mo Costandi has another great example of how our knowledge of developmental biology is being advanced through animal research. In a post entitled “Astrocytes build blood vessel scaffolds for long distance neuron migrations” he discusses how a research team led by Dr Armen Saghatelyan  used  Green Fluorescent Protein labeling and genetic modification to track the processes that control the migration of nerve cells to their correct location in the developing mouse brain.

It’s fascinating work, and you can read about it on the Neurophilosophy blog here.

 

 

So what does this basic research in developmental biology mean to medicine?

Scientists have known for some time that the brain has a limited ability to repair itself following injury, for example after a stroke, and more recent studies have identified a critical role for adult neuronal precursor cells in this recovery.  But the process by these adult neuronal precursor cells migrate to the site of injury and integrate into the damaged brain circuitry is very inefficient, with only a small number of cells reaching the correct location, so scientists are working on a variety of approaches to boost the brain’s ability to repair itself.

One approach to doing this is the use of exogenous stem cells, such as the human embryonic stem cell derived neuronal precursor cells developed by the UK-based company ReNeuron that entered clinical trials for stroke in 2011.

Another avenue being pursued by several research groups around the world is to improve the efficiency with which the endogenous neuronal precursor cells migrate to and repair damaged regions of the brain. In order to develop therapies that improve endogenous brain repair scientists first need to understand the processes that drive – and limit – neuronal precursor production, migration and integration in the developing and adult brain, so that they can modify and enhance those processes to safely  optimize repair.  The work of Dr Saghatelyan and his colleagues has provided medical science with another important piece of a puzzle that when solved will benefit many thousands of stroke victims around the world.

Paul Browne

Of Mice, Rice, Flies and Men

Animal rights activists often argue that animal models are irrelevant for human medicine, because they are ‘so different’ from us. But in fact some basics are shared across wildly distant species – something that the Nobel Committee acknowledged last year when they gave the Prize for Medicine and Physiology to Bruce Beutler and Jules Hoffmann for discovering the ‘early warning’ signals that set off immune responses in flies, mice and humans.

On Jan. 25 both Beutler, who works at the University of Texas in Dallas, and Hoffmann of the University of Strabourg, France, were at the University of California, Davis talking to a packed house about their work. Joining them on stage was UC Davis plant pathologist Pam Ronald, who studies rice, and Luke O’Neill of Trinity College Dublin, Ireland, who talked about human medicine.

(Watch the presentations here: http://ccm.ucdavis.edu/immunity.html)

L to R symposium speakers Bruce Beutler, Jules Hoffmann, Luke O'Neill and Pamela Ronald, with (far right) symposium sponsor Murray Gardner.

Work in these very different organisms can give insights that advances human medicine. From the basic discoveries in mice, flies and even rice could come new drugs and new approaches to treat heart disease, rheumatoid arthritis, inflammatory bowel disease and other conditions.

Our immune system has two lines of defense. The innate immune system reacts first, attacking invading microbes and triggering inflammation. If that response fails, the adaptive immune system fights back with antibodies and specialized killer cells. Afterward, the adaptive immune system retains a memory that allows a more rapid and powerful response if the same virus, bacterium or parasite comes back.

Only animals with backbones, from fish to humans, have an adaptive immune system. But all animals, including insects, as well as plants, have innate immune systems.

In the 1990s, Ronald (working with rice), Hoffmann (with Drosophila flies) and Beutler (with mice) identified genes for immune receptors that triggered innate immunity in the rice, flies and mice, and found that the genes were remarkably similar despite hundreds of millions of years of evolution.

From this common trigger, plants, insects and animals develop different types of response to invaders.

Activation of the immune system is not always a good thing. It can lead to allergy, inflammatory diseases such as rheumatoid arthritis or autoimmunity, when the body starts attacking its own tissues.

In his talk, for example, Beutler described how his team, working with mice, has isolated genes related to inflammatory bowel disease, while O’Neill talked about the possibility of being able to develop drugs to treat a wide range of diseases linked to inflammation.

The symposium is an annual event sponsored by a fund created by AIDS pioneer and UC Davis professor emeritus Murray Gardner, who previewed in an interview for Sacramento Public Radio Jan. 24 [http://www.capradio.org/168919] At the beginning of the AIDS epidemic in the 1980s, Gardner helped discover viruses similar to HIV in monkeys and cats – animal models that have been of vital importance in discovering drugs to treat and prevent HIV/AIDS.

– Andy Fell

An Open Letter to the Laboratory Animal Veterinary Community and Research Institution Administration

The decades following passage of the U.S. Animal Welfare Act in the 1960s are marked with wide-ranging and significant changes to the administration, oversight, and responsibility for daily operations of institutions engaged in laboratory animal research. The intent of the legislation, and the central purpose of the accompanying and continuing changes, is to best ensure the welfare of animals in research.

This goal encompasses all aspects of laboratory animal care— their participation in ethical scientific studies, their humane treatment during daily care and maintenance, and their receipt of the highest standard of clinical care. Do scientists engaged in animal research perform all of these duties?  No. In fact, by law, it is not scientists who have the ultimate responsibility for oversight of all issues involved in animal welfare, but the attending veterinarian and institutional officials.

In practice, there are a range of individuals who share in the responsibility to provide for animal welfare. Many different types of expertise are needed to provide the best management of a laboratory animal research facility. Scientists working with animals have expertise in the topic their research addresses, in the activities that research requires, and in use of animals in research. Depending on their research area, background, and training they may have tremendous depth and breadth of knowledge about the animals’ behavior, psychology, physiology, and other systems. But it takes more than this to accomplish all that is needed to maintain an animal research program.

Animal research programs always include veterinary staff to provide the animals with clinical care. They typically also include animal care staff to provide daily husbandry; behavioral management staff to provide environmental enrichment and animal training; and facility management staff who work with engineers and others to maintain clean and safe environments for the animals. In addition to facility management, clinical care, and daily husbandry there are also divisions of personnel charged with evaluation and oversight of the research, including the Institutional Animal Care and Use Committee, associated staff, and compliance officers. Oversight for the entirety of the animal research program typically rests at the level of university administration.

In sum, the number of individuals and divisions now involved in ensuring laboratory animals’ welfare and humane treatment in ethical scientific studies extends far beyond the scientists most identified with animal research.  What does this mean? It means that there is a great deal of shared responsibility for both successes and the occasional failures in the conduct of laboratory animal science.  It also means that any discussion of continued improvements in the daily activities that affect animal welfare, as well as changes in policies that govern the conduct of animal research, should benefit from teamwork among these different stakeholders.

A Veterinary Technician works with rodents

A huge number of people are involved in animal welfare in laboratories

Finally, it should mean that in public dialogue the voices of scientists and research advocates are routinely joined by laboratory animal veterinarians, university officials, and others who play important roles in laboratory animal research.  This is true even when that research is controversial and has the potential to elicit attention from animal rights activists. All too often, however, few of these voices are raised when the public eye is turned to issues of concern in animal facilities. Rather, in place of thoughtful answers to questions raised by a range of parties—by the press, by animal rights activists, by other scientists, by USDA reports— what is often offered are generic statements that contribute little to understanding of the events and the context in which they occurred. For example, in response to virtually any type of incident, an institution’s response might be along the lines of:  “We follow all regulations and hold animal welfare in highest regard and priority…”

It is long past the time that our community should have abandoned this approach and required more from each of its members and divisions.  To accept anything less is a mistake.  Absence of accurate information, accompanied by the failure of institutions and their representatives to engage in public dialogue, only further erodes public trust.

The intent of the AWA, subsequent legislation and policies, accreditation programs, revisions of guidelines, and continued increases in regulatory oversight is to ensure the best animal welfare and humane treatment possible.  In the rare cases where the apparatuses put in place to achieve this goal fail, sometimes from accident or human error, two things must happen.  First, it is contingent upon all of those involved to immediately work together to identify the reason for the failure and ways to minimize the possibility that it occurs again.  Second, those ultimately responsible for oversight should provide the public with accurate information, explanation, and opportunity for discussion.  At the very least, they should be able to articulate the rationale and their support for the research programs and their contribution to scientific and medical progress.

Are we suggesting that attending veterinarians and institutional officials open their doors for daily chats with animal rights activists?  No, but we do believe that addressing legitimate public concerns and questions about their animal research programs are among the key obligations of those charged with oversight and conduct of those programs.

While scientists can address questions about the scientific side of animal research, we need the laboratory animal care and veterinary staff to provide their expertise in service of addressing public questions about clinical care and husbandry.  If they do not, it will be no surprise if the public view of animal research is disproportionately colored by the relatively rare adverse events and the misrepresentations of animal rights activists. Many believe that it is possible—and perhaps acceptable—to ignore this part of reality in order to focus on more immediate demands for time, energy, and resources. Consider, however, that a fundamental part of the AWA, accreditation, regulation, and professional obligation is actually to ensure communication with the public that supports animal research.  Thus, it is our entire community who share a primary obligation to engage in the dialogue that surrounds us.

Speaking of Research Committee

A Proposal for the Labeling of Medicines

In a recent poll conducted by Zogby, 2,100 adults in the U.S. were asked the following question.

Do you agree or disagree with medical and scientific research that requires lab animals?

The results showed  a similar outcome to that of other recent polls.

About 52% of the population approve of animal research in various degrees, about 27% disapprove in various degrees, 15% are neutral and 6% are unsure about their position.

Despite the many polls done on the subject it remains unclear on what grounds do some people object to the use of animals in science.

Is it perhaps that they find the work morally wrong?  Is it that they believe all living beings have the basic rights to liberty and freedom?

Some insight into these questions can be gained by asking the same group of people what would the do in the following scenario.

Suppose you suffer from a leaky heart valve, and that doctors say you have two years left.   You could have a valve replacement surgery that might save your life.  But, in order to obtain the replacement tissue necessary for a surgery, a pig must be killed.

Which of the following statements best reflects what you would do if faces with a similar situation?

Statement A: I would have the surgery.  I think it is ethical.
Statement B: I would have the surgery, but I think it is unethical.
Statement C: I would not have the surgery, but I think it is ethical.
Statement D: I would not have the surgery because I think it is unethical.

Here are the results from the same poll:

Now, if one believes animals have rights they surely ought to be respected.  If you believe a pig has the same basic rights to life and freedom as your neighbor, then you ought to refuse the surgery for the same reason that you would not kill your neighbor to save your own life.

However, only a mere 3% of those asked appear ready to act in a way consistent with such a position.  It is interesting to note that also about 3% of the US population are vegetarian, although most of them do it for health reasons and not ethical objections to the use of animals as food.

Thus, those that oppose research do not appear to do so because of belief that all living beings have the same basic rights to life as that of fellow humans.

Another small minority, 2%, would not have the surgery despite the fact they think such surgical intervention is ethical.  It would appear this group simply is uncomfortable with the notion that pig tissue would be implanted in their human hearts.

About 12% of the group would opt to save their lives despite having ethical objections.  It appears this group feels there is something inherently wrong in killing an animal to allow them to survive and yet, if faced with the situation they would nonetheless go ahead with the surgery.  Arguably, this group realizes that the pig is a living being that we owe moral concern, but that when human and animal lives are at stake, opting to save the human is morally permissible.  Alternatively, they may genuinely opt for behaving in an immoral fashion when it comes to saving their own lives.

Finally, the vast majority, 73% of them, will opt for the surgery without having any moral concerns whatsoever.   None at all.   That is roughly 3 out of 4 people in the US population.

A natural question is then why wouldn’t the same group, at the very least, be in favor of animal research that advances medical knowledge and human health?

One likely possibility is that they fail to see the direct link between research and the therapies and medicines that it produces.  They fail to see that the medicine that will save their lives next time they visit the emergency room will be, in all likelihood, the result of animal research.  They may wrongly perceive basic and translational research as two being completely different things.  The contribution of basic knowledge to human health may be lost in translation.

So, what can be done?

Aside from scientists and physicians reaching out to educate the public on this matters, we could begin by labeling each and every single medication that resulted from basic research in animals with such basic information.  Note that I am not talking about safety testing in animals — which is required by the law.  Instead, I am referring to medicines developed through the identification of molecular targets or the discovery of specific mechanisms with the use of animals in basic research.  In other words, I propose to label medicine as derived from animal research if it actually produced the knowledge that actually allowed scientists to understand how a particular therapy could be developed.

Shouldn’t the public be entitled to know where their medicines come from? Shouldn’t the public be entitled to understand the range of benefits produced by their tax dollars?

What do you think?

Ignorance or Deception?

Animal rights activists may want to start cooling down their engines.

Apparently, by 2050 we can expect the complete elimination of animal use in science.

At least, this is the prediction made by Dr. Andrew Rowan, Chief Scientific Officer of the Humane Society of the United States (HSUS) in a recent article that appeared in The Scientist.

The title of the piece was “Avoiding Animal Testing.  Advances in cell-culture technologies are paving the way to the complete elimination of animals from laboratories”.

The first half of the article focuses on the development and adoption of alternatives to the use of animals in toxicology.  Our public health officials and the FDA have long made the sensible decision to require any company that introduces new chemicals or drugs into the market to provide an initial experimental assessment of their potential toxicity to humans.

This use of animals for such safety screening is typically called animal testing.

Dr. Rowan correctly points out that advances in the development toxicology methods may allow us eventually to relax the regulations that require the use of animals in testing.  But he rapidly moves to insinuate such advances imply that by 2050 we could see the end of animal use in laboratories:

This overall decline in animal use can be attributed to the advent of novel technologies such as improved cell-culture systems and micro-analytic techniques; more sophisticated model systems; improved understanding of signaling and metabolic pathways; and a host of other new methods that allow scientists to answer important questions about the functioning of healthy and diseased tissues without subjecting whole animals to harmful procedures. With a 50 percent decline in animal research since 1975, we are roughly at the halfway point towards the complete elimination of animal research. Thus, we argue that, by 2050, we might finally see the last of animal use in the laboratory, particularly if all stakeholders put their minds to it.

First, the assertion that the total use of animals is systematically declining is not supported by the data.  The slide below, for example, was taken from a recent talk Dr. Rowan gave at the University of Wisconsin.  It shows the total number of animals used has been stable since the mid 80s, with the number of non-genetically modified (Non-GM, faint dashed line) animals decreasing and stabilizing in the 90s (see also data here), while the number of  genetically modified (GM) animals, which are largely mice, has been systematically increasing.

Second, even if correctly asserting that we can expect a diminished need for animals in toxicology testing, Dr. Rowan’s generalization of such trend from a such narrow field to all of biomedical research is groundless and misleading.

Let us be clear, our universities do not engage in animal testing, but in animal research.

What’s the difference?

Scientists are largely concerned with elucidating the basic mechanisms of biological processes in health and disease.  We want to study how cells in our bodies work, how they communicate, how they develop, how they age and how they die.   We want to understand how the brain, our immune system, and internal organs work and how they fail.  And so on…

Why is it critical we develop such an understanding?

Because without this knowledge there will be no hope to combat disease. Indeed, the mission of the National Institutes of Health (NIH) recognizes this fundamental fact in its opening statement,

NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life and reduce the burdens of illness and disability.

Implicit in such declaration is the acknowledgment that it is basic knowledge that drives advancements in human health and well-being.  Basic knowledge of nature is what drives progress.  This point is critical –   translational or applied research would not exist without basic knowledge as the raw material.  Without knowledge there would be nothing to translate nor apply.

Those that declare an imminent end to the use of animals in science are effectively implying that they envisage all basic knowledge needed will be acquired by a certain date, or that we will have methods that would allow us to proceed with studies non-invasively in human volunteers. Dr. Rowan’s statement that “Advances in cell-culture technologies are paving the way to the complete elimination of animals from laboratories” is nothing short of utter scientific nonsense.

Is it possible for Dr. Rowan to be ignorant of the role of animals in scientific research?  Could he legitimately be confused about the difference between safety testing on one hand and the development of therapies and basic research on the other?

This seems highly unlikely giving his academic credentials and the fact that he has served on IACUCs before.  In fact, another slide from his talk, shows him delineating these different uses of animals, and illustrating that animal testing for human safety accounts for merely ~25% of total animal use.

No, Dr. Rowan is not confused at all.  He knows what he is talking about.  This is unfortunate as one can only conclude his article is simply a misguided attempt to deceive the public about the fields in which we might realistically expect science to successfully replace animals in the near future.

And I emphasized science above for a good reason.

As difficult as it is for animal advocates to understand, scientists also believe we will see a day when we can eliminate the use of animals in all animal research.  And the day will arrive because of the hard work, progress and achievements of dedicated scientists, such as this one, and not because of deception of those that want to oppose animal research at all cost.

For HSUS to suggest that all animal research could be eliminated by 2050 is  flatly wrong from a scientific point of view, and utterly irresponsible from a public health perspective.